1c:{"metadata":[["$","title","0",{"children":"NIH VideoCast - Dissecting Disease Biology and Advancing Medicine with Small Molecules"}],["$","meta","1",{"name":"description","content":"Pharmaceutical companies develop small-molecule therapeutic drugs in part by drawing upon government-sponsored research performed in universities and other non-profit institutions. Academic labs have recently transitioned towards the integration of small-molecule synthesis, small-molecule screens, and informatics with the primary goal of illuminating principles that underlie biology and disease. My lecture aims to provide insight into the development of one such example of the latter, the Broad Institute's Chemical Biology Program (BCB; formerly Harvard's ICCB), which is sponsored by the NCI through their Initiative for Chemical Genetics (ICG) and the NIGMS through their Centers of Excellence in Chemical Methodology and Library Development (CMLD).\n
\n
\nFor more information, visit
\nhttp://www-schreiber.chem.harvard.edu/people/sls.html\n
\n
\nWALS
"}],["$","meta","2",{"name":"publisher","content":"National Institutes of Health"}],["$","meta","3",{"property":"og:title","content":"NIH VideoCast - Dissecting Disease Biology and Advancing Medicine with Small Molecules"}],["$","meta","4",{"property":"og:description","content":"Pharmaceutical companies develop small-molecule therapeutic drugs in part by drawing upon government-sponsored research performed in universities and other non-profit institutions. Academic labs have recently transitioned towards the integration of small-molecule synthesis, small-molecule screens, and informatics with the primary goal of illuminating principles that underlie biology and disease. My lecture aims to provide insight into the development of one such example of the latter, the Broad Institute's Chemical Biology Program (BCB; formerly Harvard's ICCB), which is sponsored by the NCI through their Initiative for Chemical Genetics (ICG) and the NIGMS through their Centers of Excellence in Chemical Methodology and Library Development (CMLD).\n
\n
\nFor more information, visit
\nhttp://www-schreiber.chem.harvard.edu/people/sls.html\n
\n
\nWALS
"}],["$","meta","5",{"property":"og:url","content":"https://uat.d1rkikwu4q8tg.amplifyapp.com/watch/98b32c58-d5db-11f0-9cf9-12c45c580ad9"}],["$","meta","6",{"property":"og:site_name","content":"NIH VideoCast"}],["$","meta","7",{"property":"og:image","content":"https://nihcit.rev.vbrick.com/api/v2/media/videos/thumbnails/51a8a22a-f9b6-4764-9644-9eb0d3632784.jpg"}],["$","meta","8",{"property":"og:type","content":"website"}],["$","meta","9",{"name":"twitter:card","content":"summary_large_image"}],["$","meta","10",{"name":"twitter:title","content":"NIH VideoCast - Dissecting Disease Biology and Advancing Medicine with Small Molecules"}],["$","meta","11",{"name":"twitter:description","content":"Pharmaceutical companies develop small-molecule therapeutic drugs in part by drawing upon government-sponsored research performed in universities and other non-profit institutions. Academic labs have recently transitioned towards the integration of small-molecule synthesis, small-molecule screens, and informatics with the primary goal of illuminating principles that underlie biology and disease. My lecture aims to provide insight into the development of one such example of the latter, the Broad Institute's Chemical Biology Program (BCB; formerly Harvard's ICCB), which is sponsored by the NCI through their Initiative for Chemical Genetics (ICG) and the NIGMS through their Centers of Excellence in Chemical Methodology and Library Development (CMLD).\n
\n
\nFor more information, visit
\nhttp://www-schreiber.chem.harvard.edu/people/sls.html\n
\n
\nWALS
"}],"$L22","$L23","$L24"],"error":null,"digest":"$undefined"}